<DOC>
	<DOCNO>NCT01223976</DOCNO>
	<brief_summary>The purpose study determine level agreement QuantiFeron -TB Gold test ( QFT-G ) Tubeculin skin test ( TST ) screen latent tuberculosis patient suffer psoriasis .</brief_summary>
	<brief_title>Sensitivity Specificity QuantiFeron -TB Gold Test ( QFT-G ) Patients With Psoriasis</brief_title>
	<detailed_description>Patients psoriasis psoriatic arthritis candidate receive anti-TNF alpha therapy require prior screening latent tuberculosis ( LTB ) . Currently , screen LTB base tuberculin skin test ( TST ) , chest X ray , questionaire predisposing factor TB . The main drawback TST lack specificity due cross reactivity Bacille Calmette- Guerin ( BCG ) nontuberculosis mycobacteria risk anergy immunosuppressed patient . Furthermore , suggest skin psoriatic patient may sensitive result increased TST obligatory reflect status LTB . Recently , new assay LTBI develop , evaluate interferon ( IFN ) -γ release memory effector T-cells stimulate vitro specific mycobacterial antigen , ESAT-6 ( early secretory antigen target-6 ) CFP-10 ( culture filtrate protein-10 ) [ 9-10 ] . The QuantiFeron -TB Gold test ( QFT-G ) use ELISA measure IFN-γ concentration supernatant plate format `` In tube '' format ( QFT-GIT ) enzyme-linked immunospot ( ELISPOT ) detect individual IFN-γ produce T-cells ( TS-TB , Oxford Immunotech , Abingdon , UK ) . The whole blood IFN-γ assay approve The Centers Disease Control alternative screening strategy TST immunocompetent individual [ 11 ] , clinical utility single test detection LTBI immunocompromised patient controversial.Furthermore , utility patient psoriasis psoriatic arthritis yet establish One hundred patient psoriasis psoriatic arthritis 50 healthy control participate study . Enrolled subject request complete detailed sociodemographic TB screening questionnaire include gender , age , place birth work , prior BCG vaccination , close contact TB patient TB prophylaxis past . Screening workup includ assessment clinical disease activity use Disease Activity Score 28 ( DAS-28 ) Psoriasis Area Severity Index ( PASI ) , documentation past current treatment systemic corticosteroid immunosuppressive drug , image ( chest X-ray ) . All subject undergo TST QFT-G test A 2-TU dose PPD administer certified technician use Mantoux method induration measure 72 h. TST deem positive bove equally 5 mm RA patient 10 mm control The absence induration &lt; 2 mm diameter record anergic negative TST result define 2 less 5 mm reaction RA patient . QFT-G test The second-generation QuantiFeron® ( QIFN ) whole-blood IFN assay ( Cellestis ) perform interpreted accord manufacturer 's instruction . Briefly , test consist negative control ( nil well , i.e. , whole blood without antigen mitogen ) , positive control ( mitogen well , i.e. , whole blood stimulate mitogen phytohemagglutinin [ PHA ] ) two sample well , i.e. , whole blood stimulate either M. tuberculosis-specific antigen , Early Secretory Antigen Target 6 ( ESAT-6 ) Culture Filtrate Protein 10 ( CFP-10 ) . Five ml heparinized whole blood draw QFT-G PPD test . The blood specimen incubate 16-20 h ( overnight ) 37°C humidify atmosphere . IFN-γ level nil well consider background subtract result mitogen well antigen-stimulated well . The result consider positive concentration of.IFN-γ sample well stimulation ESAT-6 and/or CFP-10 great equal 0.35 IU/ml ( subtract value nil well ) , regardless result positive control ( mitogen well ) . The result consider negative response specific antigen ( subtract value nil well ) less 0.35 IU/ml IFN-γ level positive control ( subtract value nil well ) great equal 0.5 IU/ml . The result consider indeterminate antigen-stimulated sample well negative ( i.e. , &lt; 0.35 IU/ml subtract value Nil well ) value positive control well less 0.5 IU/ml subtract value nil well nil well . QFT-G test The second-generation QuantiFeron® ( QIFN ) whole-blood IFN assay ( Cellestis ) perform interpreted accord manufacturer 's instruction . Briefly , test consist negative control ( nil well , i.e. , whole blood without antigen mitogen ) , positive control ( mitogen well , i.e. , whole blood stimulate mitogen phytohemagglutinin [ PHA ] ) two sample well , i.e. , whole blood stimulate either M. tuberculosis-specific antigen , Early Secretory Antigen Target 6 ( ESAT-6 ) Culture Filtrate Protein 10 ( CFP-10 ) . Five ml heparinized whole blood draw QFT-G PPD test . The blood specimen incubate 16-20 h ( overnight ) 37°C humidify atmosphere . IFN-γ level nil well consider background subtract result mitogen well antigen-stimulated well . The result consider positive concentration . IFN-γ sample well stimulation ESAT-6 and/or CFP-10 great equal 0.35 IU/ml ( subtract value nil well ) , regardless result positive control ( mitogen well ) . The result consider negative response specific antigen ( subtract value nil well ) less 0.35 IU/ml IFN-γ level positive control ( subtract value nil well ) great equal 0.5 IU/ml . The result consider indeterminate antigen-stimulated sample well negative ( i.e. , &lt; 0.35 IU/ml subtract value Nil well ) value positive control well less 0.5 IU/ml subtract value nil well .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Tuberculosis</mesh_term>
	<criteria>Patients psoriasis psoriatic arthritis Aged 1890 History TB Known allergy TST Current past treatment antiTNF alpha</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>latent tuberculosis psoriasis arthritis TST QTF</keyword>
	<keyword>Screening latent tuberculosis psoriasis</keyword>
</DOC>